Compare FIGR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIGR | TVTX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.3B |
| IPO Year | 2025 | 2013 |
| Metric | FIGR | TVTX |
|---|---|---|
| Price | $31.34 | $62.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $53.22 | $40.62 |
| AVG Volume (30 Days) | ★ 3.4M | 1.6M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $506,865,000.00 | N/A |
| Revenue This Year | $69.23 | $44.76 |
| Revenue Next Year | $24.25 | $35.51 |
| P/E Ratio | $177.11 | ★ N/A |
| Revenue Growth | ★ 48.69 | N/A |
| 52 Week Low | $24.11 | $17.05 |
| 52 Week High | $78.00 | $66.24 |
| Indicator | FIGR | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 62.67 |
| Support Level | $30.68 | $53.76 |
| Resistance Level | $34.54 | $66.24 |
| Average True Range (ATR) | 2.04 | 2.59 |
| MACD | 0.55 | 0.27 |
| Stochastic Oscillator | 73.99 | 67.32 |
Figure Technology Solutions Inc is building the future of capital markets with blockchain technology. proprietary technology powers next-generation lending, trading, and investing activities in areas such as consumer credit and digital assets. Its use of the blockchain ledger allows them to serve their end customers, improve speed and efficiency, and enhance standardization and liquidity. The Company operates as a single operating and reportable segment. The company's geographical operations is within the USA, with the majority of revenue from California.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.